{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:10:28Z","timestamp":1774293028591,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1111\/tbj.13972","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T02:18:01Z","timestamp":1594088281000},"page":"1506-1512","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medical Management of newly diagnosed breast cancer in a BRCA1\/2 mutation carrier"],"prefix":"10.1155","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-0542","authenticated-orcid":false,"given":"Neelam V.","family":"Desai","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center Boston Massachusetts US"},{"name":"Harvard Medical School Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine M.","family":"Tung","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center Boston Massachusetts US"},{"name":"Harvard Medical School Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2560"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2348-2"},{"key":"e_1_2_14_5_1","unstructured":"NelsonHD FuR GoddardK MitchellJP et al. RiskAssessment Genetic Counseling and Genetic Testing for BRCA\u2010Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9430"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0775"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004975"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30891-4"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0055-6"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0114-z"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0127-5"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0009-7"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3231"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6660"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.023"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy257"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS1117"},{"key":"e_1_2_14_22_1","unstructured":"Tesaro Inc.A phase III trial of Niraparib versus Physician\u2019s Choice in HER2 negative Germline BRCA mutation\u2010positive breast cancer patients (BRAVO). Available fromhtts:\/\/clinicaltrials.gov.NCT010905592"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx505"},{"key":"e_1_2_14_24_1","unstructured":"AbbVie Inc.Phase III study of veliparib with carboplatin and paclitaxel in HER2\u2010negative advanced\/metastatic gBRCA\u2010associated breast cancer. Abstract presentation at ESMO 2019 Sept 27\u2010Oct 1 2019. LBA9."},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2425"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9682-9"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2714"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1891"},{"key":"e_1_2_14_30_1","doi-asserted-by":"crossref","unstructured":"DomchekSM Postel\u2010VinayS BangYJ et al.An open\u2010label multitumor phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA\u2010mutated (gBRCAm) HER2\u2010negative metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; December 5\u20139 2017; abstract PD6\u201011.","DOI":"10.1158\/1538-7445.SABCS17-PD6-11"},{"key":"e_1_2_14_31_1","doi-asserted-by":"crossref","unstructured":"VinayakS TolaneySM SchwatzbergL et al.Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple\u2010negative breast cancer beyond BRCA: (TOPACIO\/Keynote\u2010162). San Antonio Breast Cancer Symposium; December 4\u20138 2018; abstract PD5\u201002.","DOI":"10.1158\/1538-7445.SABCS18-PD5-02"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3100-x"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu559"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70160-3"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1007"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30111-6"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-019-0111-y"},{"key":"e_1_2_14_38_1","unstructured":"TungN et al.A Randomized Phase II Trial of neoadjuvant cisplatin vs. doxorubicin\/cyclophosphamide (AC) in women with newly diagnosed breast cancer and germline BrCa mutations. Available fromhttps:\/\/clinicaltrial.gov.NCT.01670500"},{"key":"e_1_2_14_39_1","unstructured":"SharmaP et al.Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I II or III triple negative breast cancer. Available fromhttps:\/\/clinicaltrials.gov.NCT.02413320"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.01.016"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01304"},{"key":"e_1_2_14_42_1","unstructured":"Pfizer.A phase 2 non\u2010randomized open label single arm multi\u2010center study of talazoparib for neoadjuvant treatment of germline brca1\/2 mutation patients with early triple negative breast cancer. Available fromhttps:\/\/clinicaltrials.gov.NCT.NCT03499353"},{"key":"e_1_2_14_43_1","doi-asserted-by":"crossref","unstructured":"TuttA et al.OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high\u2010risk HER2 negative breast cancer (BC) and a germline BRCA1\/2 mutation (gBRCAm) [abstract presented at 2015 ASCO annual meeting]. J Clin Oncol2015: 22 (15 suppl) abstr TPS 1109.","DOI":"10.1200\/jco.2015.33.15_suppl.tps1109"},{"key":"e_1_2_14_44_1","doi-asserted-by":"crossref","unstructured":"MillerK TongY JonesDR WalshT et al.Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Cancer Research Network BRE09\u2010146. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting May 29\u2010June 2 2015 Chicago IL. J Clin Oncol 33:5s 2015 (suppl; abstr 1082).","DOI":"10.1200\/jco.2015.33.15_suppl.1082"},{"key":"e_1_2_14_45_1","unstructured":"AbrahamJ et al.Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and\/or Germline BRCA (gBRCA) Positive Breast Cancer (PARTNER). Available fromhttps:\/\/clinicaltrials.gov.NCT03150576."}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.13972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tbj.13972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tbj.13972","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tbj.13972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:28:41Z","timestamp":1643351321000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.13972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/tbj.13972"],"URL":"https:\/\/doi.org\/10.1111\/tbj.13972","archive":["Portico"],"relation":{},"ISSN":["1075-122X","1524-4741"],"issn-type":[{"value":"1075-122X","type":"print"},{"value":"1524-4741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"2019-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}